Down Syndrome Test - The company is evaluating both RNA and DNA approaches for a Down syndrome test, and it is taking a rigorous and detailed approach to this work. The company is also sponsoring a number of clinical studies through independent third parties, the results of which will be published in peer-reviewed journals prior to the launch of any Down syndrome test that the company develops.
AttoSense HPV Test - In July, the University of Michigan published promising results in the use of the AttoSense(TM) HPV test in the Journal of Virological Methods. Results from this study showed that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via the most commonly used test for HPV DNA, may actually be infected with the virus at clinically relevant viral loads. The company is exploring various commercialization opportunities, with respect to the AttoSense HPV test, including partnering.
Senior Management Update - The company is pleased to report the addition of Mary Rose Keller to the senior management team, as vice president of clinical operations. Ms. Keller brings more than 25 years of clinical research experience across a broad range of therapeutic areas and diagnostic and treatment modalities. She has significant prior experience in all facets of clinical development working with biotech and pharmaceutical companies, academic institutions, and contract research organizations including managing numerous global regulatory submissions and approvals. Prior to joining SEQUENOM, Ms. Keller was vice president, glob
|SOURCE SEQUENOM, Inc.|
Copyright©2009 PR Newswire.
All rights reserved